---
aliases: >-
  /news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-clinical-trial
archetype: press-release
author:
  - Radhika Narayanan
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - >-
    Abbott’s FreeStyle Libre 2 CGM beats fingerstick testing in independent
    clinical trial
categories:
  - 'Medigy: Media (Press) Release'
  - 'Medigy: Digital Diabetes'
categorySlug:
  - 'medigy: media (press) release'
  - 'medigy: digital diabetes'
categoryUrl:
  - topic/medigy-media-press-release
  - topic/medigy-digital-diabetes
categoryLabel:
  - Media (Press) Release
  - Digital Diabetes
contentCategories: netspective-medigy-news-curated-content
institution:
  - id: 1928
    title: Abbott
    description: >-
      We understand that the first step to living your best life is good health.
      Everything we make is designed to help you do just that. That’s our
      commitment to building life-changing technologies that keep your heart
      healthy, nourish your body at every stage of life, help you feel and move
      better, and bring you information, medicines and breakthroughs to manage
      your health.


      For more than 130 years, we've put science and innovation to work – to
      create more possibilities for more people through the power of health. We
      adapt and respond quickly to changes in the world around us to deliver
      better solutions to help people live their best lives.
    alias: /profile /offeror/institution/abbott
    slug: abbott
    url: /profile/offeror/institution/abbott
    logo: 1928-logo.JPEG
offering: null
layOut: news-press-release-single
date: '2022-11-02'
description: '                                                    Dive Brief:  A randomized controlled trial has linked Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM) to significantly lower blood sugar'
favIconImage: null
featuredImage:
  alt: >-
    Abbott’s FreeStyle Libre 2 CGM beats fingerstick testing in independent
    clinical trial
  format: JPEG
  href: 0b3143e9-5369-5ab7-9657-95ef9e7b5e5f-featuredImage.jpeg
  size:
    - 364
    - 770
  valid: true
  workPackage: 15642
  wpAttachment:
    fileName: Curated_Featured_Image.jpg
    link: /api/v3/attachments/28555/content
featuredPdf: null
htmlMetaData:
  author: null
  description: null
  generator: null
  viewport: null
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: null
  ogimage: null
  ogsite_name: null
  ogtitle: null
  ogtype: null
  ogupdated_time: null
  ogurl: null
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: null
  keywords: null
id: 15642
identifier: News
lastMod: '2022-11-02T14:30:31.286549Z'
link:
  brand: medtechdive.com
  href: >-
    https://www.medtechdive.com/news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-cli/633770/
  original: >-
    https://www.medtechdive.com/news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-cli/633770/
href: >-
  https://www.medtechdive.com/news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-cli/633770/
original: >-
  https://www.medtechdive.com/news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-cli/633770/
mastHead: NEWS
mdName: 0b3143e9-5369-5ab7-9657-95ef9e7b5e5f.md
openGraphMetaData:
  ogdescription: null
  ogtitle: null
  ogurl: null
  ogimage: null
  ogsite_name: null
  ogtype: null
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: >-
    https://www.medtechdive.com/news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-cli/633770/
  medigyTopics:
    - 'Medigy: Media (Press) Release'
    - 'Medigy: Digital Diabetes'
  sourceUrl: >-
    https://www.medtechdive.com/news/abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-cli/633770/
openProjectWorkPackageType: Press Release
searchCategory: News
slug: >-
  medtechdive-abbotts-freestyle-libre-2-cgm-beats-fingerstick-testing-in-independent-clinical-trial
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: >-
  Abbott’s FreeStyle Libre 2 CGM beats fingerstick testing in independent
  clinical trial
via: ' '
insights_description: null
insights_name: null
viaLink: null
relatedOfferings:
  - label: Care4Sugar - Diabetes Reversal Program
    permalink: /offering/care4sugar---diabetes-reversal-program
    categories:
      - 'Symplur: Diabetes Education'
      - 'Medigy: Digital Diabetes'
      - 'Medigy: Personalized Medicine'
    offeringId: 18337
  - label: Metronom Health's Continuous Glucose Monitoring
    permalink: /offering/metronom-healths-continuous-glucose-monitoring
    categories:
      - 'Medigy: Digital Diabetes'
    offeringId: 10766
  - label: Insulia®
    permalink: /offering/insulia-r
    categories:
      - 'Healthcare IT News: Disease Management'
      - 'Symplur: Connected Care'
      - 'Medigy: Digital Diabetes'
    offeringId: 6087
twitterMetaData:
  twittercard: null
  twitterdescription: null
  twittertitle: null
  twitterimage: null
  twitterurl: null
---
<div id="readability-page-1" class="page"><div>                                                    <h3>Dive Brief:</h3> <ul> <li><span><span><span><span><span><span>A randomized controlled trial </span></span></span></span></span></span><a href="https://abbott.mediaroom.com/2022-10-06-New-Study-Published-in-The-New-England-Journal-of-Medicine-Demonstrates-Abbotts-FreeStyle-Libre-R-2-System-Has-Positive-Impacts-on-Glucose-Levels-and-Quality-of-Life" target="_blank"><span><span><span><span><span><span><span><span>has linked</span></span></span></span></span></span></span></span></a><span><span><span><span><span><span> Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM) to significantly lower blood sugar levels than fingerstick testing.</span></span></span></span></span></span></li> <li><span><span><span><span><span><span>The study, details of which </span></span></span></span></span></span><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2205650?query=featured_home" target="_blank"><span><span><span><span><span><span><span><span>were published</span></span></span></span></span></span></span></span></a><span><span><span><span><span><span> in The New England Journal of Medicine, was run by hospitals in the U.K. to test if CGMs benefit people with Type 1 diabetes and high blood glucose levels.</span></span></span></span></span></span></li> <li><span><span><span><span><span><span>Patients who used FreeStyle Libre for 24 weeks experienced a mean 0.8 percentage point decline in their blood glucose level, causing the study to hit its primary endpoint, and spent 130 minutes longer in their target range each day.</span></span></span></span></span></span></li> </ul>    <h3>Dive Insight:</h3> <p><span><span><span><span><span><span>Going into the study, the researchers were unsure if CGMs with optional alarms for high and low blood glucose levels benefit patients with Type 1 diabetes and high glycated hemoglobin levels. To clear up the uncertainty, </span></span></span></span></span></span><a href="https://clinicaltrials.gov/ct2/show/NCT03815006" target="_blank"><span><span><span><span><span><span><span><span>multiple U.K. hospitals</span></span></span></span></span></span></span></span></a><span><span><span><span><span><span> ran a randomized trial of 156 people comparing the use of Abbott’s FreeStyle Libre 2 with fingerstick testing for 24 weeks.</span></span></span></span></span></span></p> <p><span><span><span><span><span><span>Blood glucose levels in the <span>CGM</span> cohort fell by 0.8 percentage point, a magnitude of decline associated with decreased risk of complications, compared to a drop of 0.2 percentage point in the control group. The difference between the two groups was statistically significant.&nbsp;</span></span></span></span></span></span></p> <p><span><span><span><span><span><span>FreeStyle Libre also outperformed the control on other measures, according to the study. Users of the CGM spent more time in their target glucose range and 43 minutes less per day with low blood sugar. Two people in the control arm had an episode of severe low blood sugar.&nbsp;</span></span></span></span></span></span></p> <p><span><span><span><span><span><span>The study also evaluated patient satisfaction with diabetes treatment and glucose monitoring. Patients using FreeStyle Libre scored higher on the Diabetes Treatment Satisfaction Questionnaire and Glucose Monitoring Satisfaction Survey, indicating greater overall satisfaction with Abbott’s CGM than with fingerstick testing. The researchers now are evaluating whether the CGM system was cost effective.</span></span></span></span></span></span></p>                      </div></div>